RNA Interference: Application to Drug Discovery and Challenges to Pharmaceutical Development provides a general overview of this rapidly emerging field, with a strong emphasis on issues and aspects that are important to a drug development team. The first part covers more general background of RNA interference and its application in drug discovery. In the second part, the book addresses siRNA (small interfering RNA), a pharmaceutically potent form, and its use and delivery in therapeutics along with manufacturing and delivery aspects.

PAUL H. JOHNSON, PhD, is a cofounder and Chief Scientific Officer at PhaseRx, Inc. He is the author of numerous scientific papers and patents, and was the recipient of the 2007 Jeffrey Wenig Memorial Award for Outstanding Achievement in Drug Delivery.